- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00091871
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
Eosinophils are a type of white blood cell. Elevated eosinophil levels can damage the heart, nerves, and other organs, in the syndrome known as hypereosinophilic syndrome (HES). Some individuals have a hereditary form of HES known as familial eosinophilia (FE). More research on the causation and mechanisms of HES is needed in order to design more effective and less toxic therapies.
This study will investigate FE and its genetic causes, damage mechanisms, and disease markers (such as blood test abnormalities). It will enroll approximately 50 individuals (both adults and children) from a previously studied family with FE. This is a long-term study of indefinite duration.
Participants will undergo yearly clinical examinations including medical history, physical examination, bloodwork, EKG, echocardiogram, and pulmonary function tests, with additional or more frequent examinations and tests as required. In addition, participants will donate blood and tissue for research purposes. Both adult and child participants will donate blood. At the initial evaluation, adult participants will donate bone marrow. During the study, some adult participants will also undergo a limited number of leukaopheresis sessions, in which blood is donated from one arm, the blood is separated into red blood cells and other components, and the red blood cells are returned into the donor's other arm.
Study Overview
Status
Conditions
Detailed Description
Study Description:
Affected and unaffected members of families with familial hypereosinophilia (FE) will be admitted on this protocol. For affected family members, a thorough clinical evaluation will be performed every 2 years with emphasis on potential sequelae of eosinophil-mediated tissue damage. Blood cells, bone marrow and/or serum will also be collected to provide reagents (such as DNA, RNA, and specific antibodies) for use in the laboratory to address issues related to the genetic and immunologic basis of FE as well as its pathogenesis. It is anticipated that affected family members will undergo a more extensive evaluation than is generally available and that the specimens collected from them will prove to be valuable reagents for laboratory studies related to eosinophilia, eosinophil activation and function. While the study is not designed to address the question of therapy for FE, in patients for whom medical therapy is indicated (for either the hypereosinophilia itself or its sequelae), appropriate treatment will be instituted by our clinical service or the patients local physicians. No experimental chemotherapy is involved in this protocol. Unaffected family members will provide research specimens on this protocol to help determine the underlying genetic causes of FE.
Objectives:
Primary Objective: To study the natural history of familial hypereosinophilia (FE)
Secondary Objectives:
- To determine the immunologic and molecular mechanisms responsible for eosinophilia, eosinophil activation, and pathogenesis in FE
- To identify early clinical or laboratory markers of disease progression
Endpoints: Primary Endpoint: Development of eosinophilic end organ manifestations
Secondary Endpoints:
1a. Description of immunologic features of FE.
1b. Identification of genetic driver(s) of FE
2. Identification of clinical or laboratory markers that become abnormal prior to disease progression in FE
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Thomas W Brown, R.N.
- Phone Number: (301) 402-7823
- Email: browntw@mail.nih.gov
Study Contact Backup
- Name: Amy D Klion, M.D.
- Phone Number: (301) 435-8903
- Email: aklion@niaid.nih.gov
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- Recruiting
- National Institutes of Health Clinical Center
-
Contact:
- For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
- Phone Number: TTY dial 711 800-411-1222
- Email: ccopr@nih.gov
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 1-100 years of age
- Genetically related member of a previously identified family with FE
- Ability of subject to understand and the willingness to sign a written informed consent document.
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Any condition that the investigator feels put the subject at unacceptable risk for participation in the study
- Pregnancy (in family members who do not have eosinophilia)
Study Plan
How is the study designed?
Design Details
- Observational Models: Family-Based
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Affected family members
Family members with peripheral blood eosinophilia
|
Unaffected family members
Family members without peripheral blood eosinophilia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To study the natural history of familial hypereosinophilia (FE)
Time Frame: 30 years
|
Development of eosinophilic end organ manifestations
|
30 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the immunologic and molecular mechanisms responsible for eosinophilia, eosinophil activation, and pathogenesis of FE
Time Frame: 30 years
|
Description of immunologic features of FE; identification of genetic driver(s) of FE
|
30 years
|
To identify early clinical or laboratory markers of disease progression
Time Frame: 30 year
|
Identification of clinical or laboratory markers that become abnormal prior to disease progression in FE
|
30 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Amy D Klion, M.D., National Institute of Allergy and Infectious Diseases (NIAID)
Publications and helpful links
General Publications
- Rioux JD, Stone VA, Daly MJ, Cargill M, Green T, Nguyen H, Nutman T, Zimmerman PA, Tucker MA, Hudson T, Goldstein AM, Lander E, Lin AY. Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33. Am J Hum Genet. 1998 Oct;63(4):1086-94. doi: 10.1086/302053.
- Prakash Babu S, Chen YK, Bonne-Annee S, Yang J, Maric I, Myers TG, Nutman TB, Klion AD. Dysregulation of interleukin 5 expression in familial eosinophilia. Allergy. 2017 Sep;72(9):1338-1345. doi: 10.1111/all.13146. Epub 2017 Apr 18.
- Klion AD, Law MA, Riemenschneider W, McMaster ML, Brown MR, Horne M, Karp B, Robinson M, Sachdev V, Tucker E, Turner M, Nutman TB. Familial eosinophilia: a benign disorder? Blood. 2004 Jun 1;103(11):4050-5. doi: 10.1182/blood-2003-11-3850. Epub 2004 Feb 26.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 040286
- 04-I-0286
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eosinophilia
-
Wen ZhangBeijing Friendship Hospital; Tongji HospitalRecruitingIgG4-related Disease With EosinophiliaChina
-
Prince of Songkla UniversityNot yet recruiting
-
Beth Israel Deaconess Medical CenterNational Institute of Environmental Health Sciences (NIEHS)Enrolling by invitation
-
Medical University of GrazNot yet recruitingSevere Eosinophilic Asthma
-
AstraZenecaCompletedSevere Eosinophilic AsthmaSpain
-
Seoul National University Bundang HospitalUnknownAcute | Eosinophilic PneumoniaKorea, Republic of
-
McMaster UniversitySt. Joseph's Healthcare Hamilton; AstraZenecaCompletedSevere Prednisone Dependent Eosinophilic AsthmaCanada
-
National Institute of Mental Health (NIMH)Completed
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineUnknownadd-on Maintenance Treatment of Patients With Severe Eosinophilic AsthmaChina